BIOMARIN PHARMACEUTICAL INC Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value
BIOMARIN PHARMACEUTICAL INC (BMRN) had Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value of $116.81 million as of 2012-12-31, per its 10-K filed 2013-02-26.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue · last filed 2013-02-26
- 2012-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $116.81M.
- 2012-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $56.23M.
- 2012-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $169.72M.
- 2012-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value $58.37M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value |
|---|---|
| 2012-12-31 | $116.81M 10-K · filed 2013-02-26 |
| 2012-09-30 | $56.23M 10-Q · filed 2012-10-29 |
| 2012-06-30 | $169.72M 10-Q · filed 2012-08-02 |
| 2012-03-31 | $58.37M 10-Q · filed 2012-04-30 |
| 2011-12-31 | $70.74M 10-K · filed 2013-02-26 |
| 2011-09-30 | $125.91M 10-Q · filed 2011-10-31 |
| 2011-06-30 | $46.74M 10-Q · filed 2011-08-01 |
| 2010-12-31 | $76.95M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |